Published in J Immunol on November 30, 2009
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Impact of CD1d deficiency on metabolism. PLoS One (2011) 1.21
Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice. Gastroenterology (2010) 1.13
Delicate balance among three types of T cells in concurrent regulation of tumor immunity. Cancer Res (2013) 1.02
Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol (2011) 0.95
Type II NKT cells facilitate Alum-sensing and humoral immunity. J Leukoc Biol (2012) 0.87
NKT cells in sepsis. Clin Dev Immunol (2010) 0.79
Tolerance and Cross-Tolerance following Toll-Like Receptor (TLR)-4 and -9 Activation Are Mediated by IRAK-M and Modulated by IL-7 in Murine Splenocytes. PLoS One (2015) 0.76
Simplexide induces CD1d-dependent cytokine and chemokine production from human monocytes. PLoS One (2014) 0.75
CD1d-mediated activation of group 3 innate lymphoid cells drives IL-22 production. EMBO Rep (2016) 0.75
The biology of NKT cells. Annu Rev Immunol (2007) 14.43
NKT cells: what's in a name? Nat Rev Immunol (2004) 7.84
Lysosomal glycosphingolipid recognition by NKT cells. Science (2004) 7.31
CD1: antigen presentation and T cell function. Annu Rev Immunol (2004) 6.89
Recognition of bacterial glycosphingolipids by natural killer T cells. Nature (2005) 6.38
Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest (2004) 5.16
Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med (2000) 3.93
Regulation of NKT cell development by SAP, the protein defective in XLP. Nat Med (2005) 3.62
Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity (2002) 3.46
The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol (2007) 3.34
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
Regulation of immunity by self-reactive T cells. Nature (2005) 2.63
CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J Exp Med (1999) 2.53
Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J Exp Med (1999) 2.42
alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci U S A (2000) 2.30
Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci U S A (2007) 2.24
CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med (2002) 2.22
Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis (2003) 1.91
Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J Immunol (2008) 1.90
CD1d ligands: the good, the bad, and the ugly. J Immunol (2006) 1.89
Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci U S A (2007) 1.84
Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J Virol (2003) 1.83
Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol (2003) 1.81
Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant V alpha 14-J alpha 281 TCR. J Immunol (2003) 1.72
A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol (1999) 1.69
Regulation of CD1d expression and function by a herpesvirus infection. J Clin Invest (2005) 1.64
CD1-restricted T cells in host defense to infectious diseases. Curr Top Microbiol Immunol (2007) 1.62
Innate immune response to encephalomyocarditis virus infection mediated by CD1d. Immunology (2003) 1.57
NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol (2002) 1.55
To be or not to be NKT: natural killer T cells in the liver. Hepatology (2004) 1.49
A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol (2001) 1.47
NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol (2008) 1.46
CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology (2000) 1.46
CD1-restricted T cells and tumor immunity. Curr Top Microbiol Immunol (2007) 1.45
CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J Leukoc Biol (2001) 1.44
Ligation of intestinal epithelial CD1d induces bioactive IL-10: critical role of the cytoplasmic tail in autocrine signaling. Proc Natl Acad Sci U S A (1999) 1.42
CD1 expression on antigen-presenting cells. Curr Top Microbiol Immunol (2007) 1.42
CD1d ligation on human monocytes directly signals rapid NF-kappaB activation and production of bioactive IL-12. Proc Natl Acad Sci U S A (2005) 1.40
NK cell-like behavior of Valpha14i NK T cells during MCMV infection. PLoS Pathog (2008) 1.39
Cutting edge: Compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. J Immunol (2002) 1.37
HIV-1 down-regulates the expression of CD1d via Nef. Eur J Immunol (2006) 1.36
Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J Virol (2003) 1.35
Cutting edge: a role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol (2000) 1.33
Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol (2004) 1.27
Cutting edge: the IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: exploring the role of GPIs in NK T cell activation and antimalarial responses. J Immunol (2000) 1.26
Role of CD1d in coxsackievirus B3-induced myocarditis. J Immunol (2003) 1.22
Isolation and expression of cDNA encoding the murine homologues of CD1. J Immunol (1991) 1.20
Impaired cell surface expression of human CD1d by the formation of an HIV-1 Nef/CD1d complex. Virology (2005) 1.19
Tissue distribution, regulation and intracellular localization of murine CD1 molecules. Mol Immunol (1998) 1.14
Cutting edge: anti-CD1 monoclonal antibody treatment reverses the production patterns of TGF-beta 2 and Th1 cytokines and ameliorates listeriosis in mice. J Immunol (1999) 1.13
Innate immunity: NKT cells in the spotlight. Curr Biol (2005) 1.11
IFN-beta-mediated up-regulation of CD1d in bacteria-infected APCs. J Immunol (2006) 1.07
The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol (2004) 1.06
Natural killer T cells and innate immune B cells from lupus-prone NZB/W mice interact to generate IgM and IgG autoantibodies. Eur J Immunol (2008) 1.06
Inhibition of CD1d1-mediated antigen presentation by the vaccinia virus B1R and H5R molecules. Eur J Immunol (2006) 1.05
Viral danger signals control CD1d de novo synthesis and NKT cell activation. Eur J Immunol (2008) 1.03
Inhibition of CD1 antigen presentation by human cytomegalovirus. J Virol (2008) 1.02
CD1 antigen presentation by human dendritic cells as a target for herpes simplex virus immune evasion. J Immunol (2006) 1.01
Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci (2006) 0.98
Chewing the fat on natural killer T cell development. J Exp Med (2006) 0.96
Activation of nonclassical CD1d-restricted NK T cells induces airway hyperreactivity in beta 2-microglobulin-deficient mice. J Immunol (2008) 0.95
Natural killer T cells: know thyself. Proc Natl Acad Sci U S A (2007) 0.94
Inhibition of CD1d activation suppresses septic mortality: a role for NK-T cells in septic immune dysfunction. J Surg Res (2003) 0.93
CD1d-based combination therapy eradicates established tumors in mice. J Immunol (2009) 0.92
CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo. J Virol (2006) 0.91
NKT cells are not critical for HSV-1 disease resolution. Immunol Cell Biol (2005) 0.91
Human immunodeficiency virus gp120 downregulates CD1d cell surface expression. Immunol Lett (2004) 0.91
Reduction in CD1d expression on dendritic cells and macrophages by an acute virus infection. J Leukoc Biol (2004) 0.90
NKT cells and HIV infection. Microbes Infect (2003) 0.89
CD1d activation and blockade: a new antitumor strategy. J Immunol (2009) 0.87
Generation of cellular immunity to lymphocytic choriomeningitis virus is independent of CD1d1 expression. Immunology (2001) 0.86
NK cell activation and protection occur independently of natural killer T cells during Trypanosoma cruzi infection. Int Immunol (2005) 0.84
Type I IFN-producing CD4 Valpha14i NKT cells facilitate priming of IL-10-producing CD8 T cells by hepatocytes. J Immunol (2007) 0.82
CD1 stimulation of human T cell lines induces a rapid increase in the intracellular free Ca2+ concentration and the production of IL-2. J Immunol (1990) 0.81
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem (2004) 3.51
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell (2011) 2.86
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity (2012) 2.80
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res (2006) 2.46
Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol (2008) 2.35
Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem (2002) 2.28
The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem (2004) 2.15
Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res (2014) 2.15
SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res (2008) 1.96
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res (2007) 1.84
Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci U S A (2007) 1.84
Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res (2009) 1.76
Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci U S A (2006) 1.75
AR and ER interaction with a p21-activated kinase (PAK6). Mol Endocrinol (2002) 1.60
SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res (2007) 1.57
Innate immune response to encephalomyocarditis virus infection mediated by CD1d. Immunology (2003) 1.57
Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. Urology (2009) 1.56
The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner. Immunology (2006) 1.44
CD1d ligation on human monocytes directly signals rapid NF-kappaB activation and production of bioactive IL-12. Proc Natl Acad Sci U S A (2005) 1.40
ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest (2013) 1.38
Cutting edge: Compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. J Immunol (2002) 1.37
Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol (2006) 1.33
Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur J Immunol (2008) 1.32
CD1d and invariant NKT cells at the human maternal-fetal interface. Proc Natl Acad Sci U S A (2002) 1.30
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer (2011) 1.28
Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis. Hepatology (2008) 1.27
Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol (2004) 1.27
Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins. Prostate (2008) 1.24
Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1. J Biol Chem (2009) 1.19
Impaired cell surface expression of human CD1d by the formation of an HIV-1 Nef/CD1d complex. Virology (2005) 1.19
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett (2008) 1.17
Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol (2002) 1.17
A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4. J Biol Chem (2003) 1.16
Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res (2007) 1.15
Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferon-mediated immunity. Nat Immunol (2011) 1.14
Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol (2007) 1.13
Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem (2012) 1.13
Clonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Res (2012) 1.12
Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction. Mol Cell Biol (2006) 1.12
Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate (2005) 1.11
Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol (2004) 1.10
Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J Biol Chem (2007) 1.08
Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res (2011) 1.07
Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res (2009) 1.07
Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate (2008) 1.06
Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. J Clin Invest (2010) 1.06
A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int (2008) 1.06
CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci U S A (2003) 1.06
Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cells. J Immunol (2013) 1.05
T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology (2012) 1.03
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res (2008) 1.01
Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor. Mol Cancer Ther (2008) 0.99
The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation. Immunology (2005) 0.99
Historical biogeography and diversification of truffles in the Tuberaceae and their newly identified southern hemisphere sister lineage. PLoS One (2013) 0.98
Reticulated acanthoma with sebaceous differentiation. Lack of association with Muir-Torre syndrome. Am J Dermatopathol (2009) 0.96
CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. Exp Dermatol (2005) 0.96
Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide. Cancer Res (2006) 0.96
The A2aR adenosine receptor controls cytokine production in iNKT cells. Eur J Immunol (2010) 0.96
SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer. J Biol Chem (2013) 0.95
Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol (2011) 0.95
Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation. J Biol Chem (2011) 0.94
Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide. PLoS One (2010) 0.94
Activation of p21-activated kinase 6 by MAP kinase kinase 6 and p38 MAP kinase. J Biol Chem (2004) 0.93
NKT-cell-based immunotherapies in clinical trials. Clin Immunol (2011) 0.93
Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells. J Immunol (2008) 0.92
CD1d-based combination therapy eradicates established tumors in mice. J Immunol (2009) 0.92
CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo. J Virol (2006) 0.91
Gestation stage-dependent mechanisms of invariant natural killer T cell-mediated pregnancy loss. Proc Natl Acad Sci U S A (2006) 0.90
Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem Biol (2013) 0.89
Human invariant NKT cell subsets differentially promote differentiation, antibody production, and T cell stimulation by B cells in vitro. J Immunol (2013) 0.89
Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer. Cancer Cell (2009) 0.89
Role of the NK cell-activating receptor CRACC in periodontitis. Infect Immun (2012) 0.88
Biomechanical evaluation of classic solid and novel all-soft suture anchors for glenoid labral repair. Arthroscopy (2012) 0.88
Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene. J Biol Chem (2004) 0.88
Natural killer T cell-based cancer immunotherapy. Clin Cancer Res (2006) 0.88
CD1d activation and blockade: a new antitumor strategy. J Immunol (2009) 0.87
Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer (2009) 0.86
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology (2002) 0.86
Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biol Ther (2007) 0.86
Loss of effector and anti-inflammatory natural killer T lymphocyte function in pathogenic simian immunodeficiency virus infection. PLoS Pathog (2012) 0.86